Oncotarget

Research Papers:

Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae

Roger Sun, Ines Koubaa, Elaine Johanna Limkin, Isabelle Dumas, Enrica Bentivegna, Eduardo Castanon, Sébastien Gouy, Cynthia Baratiny, Fyo Monnot, Pierre Maroun, Samy Ammari, Elise Zareski, Corinne Balleyguier, Éric Deutsch, Philippe Morice, Christine Haie-Meder and Cyrus Chargari _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:9299-9310. https://doi.org/10.18632/oncotarget.24271

Metrics: PDF 1556 views  |   HTML 3612 views  |   ?  


Abstract

Roger Sun1,2, Ines Koubaa3, Elaine Johanna Limkin1,2, Isabelle Dumas4, Enrica Bentivegna5, Eduardo Castanon6, Sébastien Gouy5, Cynthia Baratiny1, Fyo Monnot1, Pierre Maroun1, Samy Ammari3, Elise Zareski3, Corinne Balleyguier3, Éric Deutsch1,2,7, Philippe Morice5,7, Christine Haie-Meder1 and Cyrus Chargari1,2,8,9

1Department of Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France

2INSERM U1030 Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France

3Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France

4Department of Medical Physics, Gustave Roussy Cancer Campus, Villejuif, France

5Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France

6Department of Drug development, Gustave Roussy Cancer Campus, Villejuif, France

7Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France

8Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France

9French Military Health Service Academy, Ecole du Val-de-Grace, Paris, France

Correspondence to:

Cyrus Chargari, email: [email protected]

Keywords: cervical cancer; locally advanced; brachytherapy; bladder invasion; vesicovaginal fistula

Received: August 29, 2017     Accepted: January 01, 2018     Published: January 18, 2018

ABSTRACT

Objective: We report outcomes of cervical cancer patients with bladder invasion (CCBI) at diagnosis, with focus on the incidence and predictive factors of vesicovaginal fistula (VVF).

Results: Seventy-one patients were identified. Twenty-one (30%) had para-aortic nodal involvement. Eight had VVF at diagnosis. With a mean follow-up time of 34.2 months (range: 1.9 months–14.8 years), among 63 patients without VVF at diagnosis, 15 (24%) developed VVF. A VVF occurred in 19% of patients without local relapses (9/48) and 40% of patients with local relapse (6/15). Two-year overall survival (OS), disease-free survival (DFS) and local control rates were 56.4% (95% CI: 44.1–67.9%), 39.1% (95% CI: 28.1–51.4%) and 63.8% (95% CI: 50.4–75.4%), respectively. Para-aortic nodes were associated with poorer OS (adjusted HR = 3.78, P-value = 0.001). In multivariate analysis, anterior tumor necrosis on baseline MRI was associated with VVF formation (63% vs 0% at 1 year, adjusted-HR = 34.13, 95% CI: 4.07–286, P-value = 0.001), as well as the height of the bladder wall involvement of >26 mm (adjusted-HR = 5.08, 95% CI: 1.38–18.64, P-value = 0.014).

Conclusions: A curative intent strategy including brachytherapy is feasible in patients with CCBI, with VVF occurrence in 24% of the patients. MRI patterns help predicting VVF occurrence.

Methods: Patients with locally advanced CCBI treated with (chemo)radiation ± brachytherapy in our institute from 1989 to 2015 were analyzed. Reviews of baseline magnetic resonance imaging (MRI) scans were carried out blind to clinical data, retrieving potential parameters correlated to VVF formation (including necrosis and tumor volume).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24271